Jindal Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.48 M
- Company Age 35 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 3.00 M
About Jindal Medicines
Jindal Medicines Pvt Ltd (JMPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 07 November 1989 and has a history of 35 years and two months. Its registered office is in Jalandhar, Punjab, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.48 M.
The company has closed loans amounting to ₹3.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Lovkesh Jindal, Ashok Jindal, Kushal Jindal, and One other member serve as directors at the Company.
Company Details
-
Location
Jalandhar, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232PB1989PTC009847
-
Company No.
009847
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Nov 1989
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Jindal Medicines?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lovkesh Jindal
|
Director | 12-May-2004 | Current |
|
Ashok Jindal
|
Director | 07-Nov-1989 | Current |
|
Kushal Jindal
|
Director | 01-Jun-2004 | Current |
|
Neelam Jindal
|
Director | 26-Sep-1997 | Current |
Financial Performance of Jindal Medicines.
Jindal Medicines Pvt Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jindal Medicines?
In 2017, Jindal Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹3.00 M
Charges Breakdown by Lending Institutions
- Uco Bank : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jul 2005 | Uco Bank | ₹3.00 M | Satisfied |
How Many Employees Work at Jindal Medicines?
Unlock and access historical data on people associated with Jindal Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jindal Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jindal Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.